-
Posted by
Two Blokes Apr 15 -
Filed in
Stock
-
5 views
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral rating highlights risks like high entry barriers, competition, and potential need for additional financing, impacting VK2735's commercial viability. Despite strong Phase II data, VK2735 faces competition from innovative obesity treatments, and strategic partnerships or buyouts could be crucial for Viking's success.
